HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by ADAMS, C. E. Articles by DAVID, A. S. Search for Related Content PubMed PubMed Citation Articles by ADAMS, C. E. Articles by DAVID, A. S.

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

Cochrane Schizophrenia Group, Summertown Pavilion, Oxford

SEEMA QURAISHI, MSc and ANTHONY S. DAVID, FRCPsych

Institute of Psychiatry & Guy's, King's and St Thomas' School of Medicine, London

Correspondence: Professor Anthony S. David, Institute of Psychiatry & GKT School of Medicine, Denmark Hill, London SE5 8AF, UK. Tel: 020 7848 0138; Fax: 020 7848 0572; e-mail: a.david{at}iop.kcl.ac.uk

Declaration of interest Funded by the NHS Health Technology Assessment programme. A.S.D. is participating in a trial funded by janssen-Cilag and has been an advisor for them. The Cochrane Schizophrenia Group has received funding from pharmaceutical companies, the NHS and Department of Health.

See pp. 300– 307, this issue.

Background Long-acting depot antipsychotic medication is a widely used treatment for schizophrenia.

Aims To synthesise relevant systematic Cochrane reviews.

Method The Cochrane Database was searched and summary data were extracted from randomised controlled clinical trials of depots.

Results Standard dose depot v. placebo resulted in significantly less relapse but more movement disorders. Those on depots (v. oral drugs) showed more global change on one outcome measure; relapse and adverse effects showed no difference. Comparisons showed no convincing advantages for one depot over another.

Conclusions Depot antipsychotics are safe and effective. They may confer a small benefit over oral drugs on global outcome. Those for whom depots are most indicated may not be represented. Large studies are required to discern differences in relapse rates and long-term adverse effects, and data on satisfaction, quality of life and economics.

Related articles in BJP:

Highlights of this issue

ELIZABETH WALSH
BJP 2001 179: 0. [Full Text]  

Systematic review of patient and nurse attitudes to depot antipsychotic medication

JESSICA WALBURN, RICHARD GRAY, KEVIN GOURNAY, SEEMA QURAISHI, and ANTHONY S. DAVID
BJP 2001 179: 300-307. [Abstract] [Full Text]  

This article has been cited by other articles:

				B. Zhu, H. Ascher-Svanum, L. Shi, D. Faries, W. Montgomery, and S. R. Marder Time to Discontinuation of Depot and Oral First-Generation Antipsychotics in the Usual Care of Schizophrenia Psychiatr Serv, March 1, 2008; 59(3): 315 - 317. [Abstract] [Full Text] [PDF]

				J. M. Kane and S. Leucht Unanswered Questions in Schizophrenia Clinical Trials Schizophr Bull, March 1, 2008; 34(2): 302 - 309. [Full Text] [PDF]

				P. N. Mahadun and M. Marshall Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics Psychiatr. Bull., February 1, 2008; 32(2): 53 - 56. [Abstract] [Full Text] [PDF]

				J. A. Lieberman Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry, October 1, 2006; 63(10): 1069 - 1072. [Full Text] [PDF]

				P. M Haddad and O. Niaz What works in schizophrenia: Depot preparations may improve outcomes BMJ, August 12, 2006; 333(7563): 353 - 353. [Full Text]

				M. X. Patel and A. S. David Why aren't depot antipsychotics prescribed more often and what can be done about it? Advan. Psychiatr. Treat., May 1, 2005; 11(3): 203 - 211. [Abstract] [Full Text] [PDF]

				T. H. Turner Long term outcome of treating schizophrenia BMJ, November 6, 2004; 329(7474): 1058 - 1059. [Full Text] [PDF]

				S. J. Keith, L. Pani, B. Nick, R. Emsley, L. San, M. Turner, R. Conley, P. Scully, P. S. Chue, and B. Lachaux Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia Psychiatr Serv, September 1, 2004; 55(9): 997 - 1005. [Abstract] [Full Text] [PDF]

				C. Paton and C. Okocha Risperidone long-acting injection: the first 50 patients Psychiatr. Bull., January 1, 2004; 28(1): 12 - 14. [Abstract] [Full Text] [PDF]

				M. Fayek, C. Flowers, D. Signorelli, and G. Simpson Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry Psychiatr Serv, November 1, 2003; 54(11): 1453 - 1456. [Full Text] [PDF]

				J. M. Kane, M. Eerdekens, J.-P. Lindenmayer, S. J. Keith, M. Lesem, and K. Karcher Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic Am J Psychiatry, June 1, 2003; 160(6): 1125 - 1132. [Abstract] [Full Text] [PDF]

				OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02) Evid. Based Nurs., January 1, 2003; 6(1): e1 - 1. [Full Text] [PDF]

				P. McGorry Review: depot antipsychotics are effective and safe for schizophrenia or schizophrenia like illnesses Evid. Based Ment. Health, May 1, 2002; 5(2): 42 - 42. [Full Text] [PDF]

				S. Reeves and R. Howard Depot injections and nut allergy The British Journal of Psychiatry, February 1, 2002; 180(2): 188 - 188. [Full Text] [PDF]

				J. WALBURN, R. GRAY, K. GOURNAY, S. QURAISHI, and A. S. DAVID Systematic review of patient and nurse attitudes to depot antipsychotic medication The British Journal of Psychiatry, October 1, 2001; 179(4): 300 - 307. [Abstract] [Full Text] [PDF]